At the United European Gastroenterology (UEG) congress in Barcelona, Spain, Japanese pharma giant Takeda presented real-world safety data for its gut-selective biologic Entyvio (vedolizumab), compared to anti-TNF伪 biologics, in patients with gastrointestinal (GI) diseases ulcerative colitis (UC) and Crohn鈥檚 disease (CD).
First approved in 2014 in Europe and the US, Entyvio is a humanised monoclonal antibody acting to antagonise the 伪4尾7 integrin, a mediator of GI inflammation.
Entyvio differs from anti-TNF伪s because it is a 鈥渟elective, rather than systemic鈥� biologic therapy, explains Takeda Global Gastroenterology Outcomes Research head Michelle Luo.
She notes the aim of this real-world data was to supplement clinical trial data already collected by Takeda about Entyvio, to support physicians in making more informed treatment decisions for their patients.
What were the real-world findings?
In the real-world retrospective chart review study EVOLVE, which analysed data from 1,000 biologic-na茂ve patients, the incidence rates of both the first occurrence of a serious adverse event and serious infections, including GI infections, were much lower for those treated with Entyvio, compared to patients treated with any of four comparator anti-TNF伪 therapies.
The treatments in question are AbbVie鈥檚 Humira (adalimumab), Janssen鈥檚 Remicade (infliximab) and Simponi (golimumab), as well as UCB鈥檚 Cimzia (certolizumab pegol).
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe incidence rate of the first serious adverse event for Entyvio was 4.6, compared to 10.3 for the anti-TNF伪 therapies. The frequency of serious infections was 1.4 for Entyvio and 2.6 for the anti-TNF伪s, with only 1% of Entyvio patients experiencing a gastrointestinal infection, compared to 4.3% of the anti-TNF伪 patients.
The EVOLVE trial data builds on results from a recent head-to-head study between Entyvio and Humira, the best-selling drug in the US. Luo notes: 鈥淥ur VARSITY study looked at Entyvio versus one particular anti-TNF伪 and only in UC. [However,] the EVOLVE study broadens into the whole anti-TNF伪 class and is not just in UC, but CD as well.鈥�
Benefits of Entyvio real-world data for patients
Although not originally intended for investigational purposes, 鈥渢his real-world study helps to enhance our overall understanding around Entyvio relative to the anti-TNF伪 class,鈥� particularly in terms of 鈥渉ow the drug is working in real-world, practice settings,鈥� Luo explains.
This, in turn, helps the treating physician and patient to better evaluate different treatment and improve their clinical management of these two GI inflammatory conditions. The positive results of the EVOLVE trial are also undoubtedly commercially significant for Takeda.
Luo concludes: 鈥淩eal world data is very useful for all diseases, but it is very important for the GI space because UC and CD are chronic conditions.鈥� This means that patients benefit from better understanding of the long-term benefit of the drugs, which is the advantage of post-marketing real world studies as a supplement to clinical trials.
